Trials / Terminated

TerminatedNCT02267317

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Phase 2 Study of The Role of Pharmacologic Inhibition of TLR4 With E5564 on Glucose Metabolism in Insulin Resistant Subjects.

Status: Terminated
Phase: Phase 2
Study type: Interventional
Enrollment: 15 (actual)

Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: Accepted

Summary

To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.

Detailed description

E5564 = Eritoran

Conditions

Insulin Sensitivity

Interventions

Type	Name	Description
DRUG	Eritoran	Pharmacologic inhibitor of TLR4 receptors.
DRUG	D5W	5% Dextrose Water = Vehicle

Timeline

Start date: 2015-01-01
Primary completion: 2018-09-01
Completion: 2018-09-01
First posted: 2014-10-17
Last updated: 2020-03-04
Results posted: 2020-03-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02267317. Inclusion in this directory is not an endorsement.